In vitro and in vivo antidiabetic potential of extracts and a furostanol saponin from Balanites aegyptiaca
Date
2017
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Taylor & Francis
Series Info
Pharmaceutical biology;55:1, 1931-1936
Scientific Journal Rankings
Abstract
Context:Balanites aegyptiacaDel. (Zygophyllaceae) fruits are well-known antidiabetic drug in Egyptian folk medicine. Nevertheless, its mechanism of action is still unclear. Objectives:Searching for the possible mechanisms of action of the plant and identification of its bio- active compounds. Materials and methods:A bio-guided protocol based on the evaluation ofa-glucosidase (AG) and aldose reductase (AR) inhibitory activities was adopted to isolate the biologically active compounds from the methanol extract (MeEx). Anin vivoantidiabetic study was conducted for the active extract, fraction and compound using streptozotocin-induced diabetic male albino Wistar rats at two dose levels (100 and 200 mg/kg.b/wt) for 2 weeks. Results:Three compounds were isolated and identified: a sterol, (1) stigmasterol-3-O-b- D-glucopyranoside; a pregnane glucoside, (2) pregn-5-ene-3b,16b,20(R)-trio1-3-O-b- D-glucopyranoside; a furostanol saponin, (3)26-(O-b- D-glucopyranosyl)-22-O-methylfurost-5-ene-3b,26-diol-3-O-b-D-glucopyranosyl-(1!4)-[a-L-rham- nopyranosyl-(1!2)]-b- D-glucopyranoside. Only compound3possessed significant AG and AR inhibitory activities (IC 50 ¼3.12 ± 0.17 and 1.04 ± 0.02lg/mL, respectively), while compounds1and2were inactive. Thein vivoantidiabetic study revealed that MeEx and furostanol saponin3possessed significant activities at a dose of 200mg/kg through reducing the fasting plasma glucose level by 46.14% and 51.39%, respect- ively, as well as reducing the total cholesterol by 24.44% and 31.90%, respectively. Compound3also caused increment in insulin and C-peptide levels by 63.56% and 65%, respectively. Discussion and conclusions:We presented a scientific base for usingBalanites aegyptiaca, and shed the light on one of its saponins, as an antidiabetic agent in fasting and postprandial hyperglycaemia along with the improvement of diabetic complications.
Description
MSA Google Scholar
Keywords
Diabetic complications, pregnanes, insulin, C-peptides, desert date
Citation
Abdel Motaal A, El-Askary H, Crockett S, Kunert O, Sakr B, Shaker S, Grigore A, Albulescu R, Bauer R. 2015. Aldose reductase inhibition of a saponin-rich fraction and new furostanol saponin derivatives from Balanites aegyptiaca. Phytomedicine. 22:829–836. Agrawal PK, Jain DC, Gupta RK, Thakur RS. 1985. Carbon-13 NMR spec- troscopy of steroidal sapogenins and steroidal saponins. Phytochemistry. 24:2479–2496. Brosky G, Logothetopoulos J. 1969. Streptozotocin diabetes in the mouse and Guinea pig. Diabetes. 18:606–611. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. 1974. Enzymatic deter- mination of total serum cholesterol. Clin Chem. 20:470–475. Campbell LK, White JR, Campbell RK. 1996. Acarbose: its role in the treat- ment of diabetes mellitus. Ann Pharmacother. 30:1255–1262. Cheyne GA, Gilmore EA. 1973. Stability of the blood glucose colour complex with 4-aminophenazone as oxygen acceptor. Med Lab Technol. 30:191–192. Chothani DL, Vaghasiya HU. 2011. A review onBalanites aegyptiacaDel (desert date): phytochemical constituents, traditional uses, and pharmaco- logical activity. Phcog Rev. 5:55–62. Fossati P, Prencipe L. 1982. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 28:2077–2080. Guzm an A, Guerrero RO. 2005. Inhibition of aldose reductase by herbs extracts and natural substances and their role in prevention of cataracts. Rev Cubana Plant Med. 10:3–4. Hara S, Okabe H, Mihashi K. 1987. Gas-liquid chromatographic separation of aldose enantiomers as trimethylsilyl ethers of methyl 2-(polyhydroxyalkyl)- thiazolidine-4(R)-carboxylates. Chem Pharm Bull. 35:501–506. Hosny M, Khalifa T, Calis I, Wright AD, Sticher O. 1992. Balanitoside, a furostanol glycoside, and 6-methyldiosgenin fromBalanites aegyptiaca. Phytochemistry. 31:3565–3569. Jackson JE, Bressler R. 1981. Clinical pharmacology of sulphonylurea hypo- glycaemic agents: part 1. Drugs. 22:211–245. Ju arez-Rojop IE, D ıaz-Zagoya JC, Ble-Castillo JL, Miranda-Osorio PH, Castell-Rodr ıguez AE, Tovilla-Z arate CA, Rodr ıguez-Hern andez A, Aguilar-Mariscal H, Ram on-Fr ıas T, Berm udez-Oca ~ na DY. 2012. Hypoglycemic effect ofCarica papayaleaves in streptozotocin-induced diabetic rats. BMC Complement Altern Med. 12:236. Judzewitsch RG, Pfeifer MA, Best JD, Beard JC, Halter JB, Porte D Jr. 1982. Chronic chlorpropamide therapy of noninsulin-dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose. J Clin Endocrinol Metab. 55:321–328. Kamel MS. 1998. A furostanol saponin from fruits ofBalanites aegyptiaca. Phytochemistry. 48:755–757. Kamel MS, Koskinen A. 1995. Pregnane glycosides from fruits ofBalanites aegyptiaca. Phytochemistry. 40:1773–1775. King AJ. 2012. The use of animal models in diabetes research. Br J Pharmacol. 166:877–894. Li H, Song F, Xing J, Tsao R, Liu Z, Liu S. 2009. Screening and structural characterization ofa-glucosidase inhibitors from Hawthorn leaf flavonoids extract by ultrafiltration LC-DAD-MSn and SORI-CID FTICR MS. J Am Soc Mass Spectrom. 20:1496–1503. Matsui T, Tanaka T, Tamura S, Toshima A, Tamaya K, Miyata Y, Tanaka K, Matsumoto K. 2007. alpha-Glucosidase inhibitory profile of catechins and theaflavins. J Agric Food Chem. 55:99–105. Motaal AA, Shaker S, Haddad PS. 2012. Antidiabetic activity of standardized extracts ofBalanites aegyptiacafruits using cell-based bioassays. Phcog J. 4:20–24. Murugan P, Pari L. 2006. Effect of tetrahydrocurcumin on lipid peroxidation and lipids in streptozotocin–nicotinamide-induced diabetic rats. Basic Clin Pharmacol Toxicol. 99:122–127. Nishimura C, Yamaoka T, Mizutani M, Yamashita K, Akera T, Tanimoto T. 1991. Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system. Biochim Biophys Acta. 1078:171–178. Patel MB, Mishra SM. 2009. Aldose reductase inhibitory activity of a C-glyco- sidic flavonoid derived fromEnicostemma hyssopifolium. J Complement Integr Med. 6:1. Rajalingam R, Srinivasan N, Govindarajulu P. 1993. Effects of alloxan induced diabetes on lipid profiles in renal cortex and medulla of mature albino rats. Indian J Exp Biol. 31:577–579. Ridhay A, Noor A, Soekamto NH, Harlim T, van Altena I. 2012. A stigmas- terol glycoside from the root wood ofMelochia umbellata(Houtt) Stapf var.degrabrataK. Indones J Chem. 12:100–103. Robinson KM, Begovic ME, Rhinehart BL, Heineke EW, Ducep JB, Kastner PR, Marshall FN, Danzin C. 1991. New potent alpha-glucohydrolase inhibitor MDL 73945 with long duration of action in rats. Diabetes. 40:825–830. Sheetz MJ, King GL. 2002. Molecular understanding of hyperglyce- mia's adverse effects for diabetic complications. JAMA. 288:2579–2588. Shirwaikar A, Rajendran K, Punitha IS. 2005. Antidiabetic activity of alco- holic stem extract ofCoscinium fenestratumin streptozotocin-nicotinamide induced type 2 diabetic rats. J Ethnopharmacol. 97:369–374. Yabe-Nishimura C. 1998. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev. 50:21–33.